Alamar Biosciences (ALMR)

The company’s core platform is Precision Proteomics, built on its proprietary NULISA technology, short for NUcleic Acid Linked Immuno-Sandwich Assay. NULISA combines immunoassay-based protein recognition with nucleic acid readout methods, enabling highly specific quantification of low-abundance proteins that can be difficult to measure using conventional techniques. This capability is important in areas such as neurology, immunology, oncology, inflammation, and early disease detection, where subtle changes in protein expression may provide meaningful biological signals.

Alamar commercialises the platform through instruments, consumables, and related services. Its product line includes NULISAseq Panels, which use sequencing-based readouts, and NULISAqpcr Assays, which use quantitative PCR workflows. These offerings are aimed at researchers seeking scalable and sensitive protein analysis for biomarker discovery, translational medicine, and potential liquid biopsy applications.

As a listed biotechnology tools company, Alamar does not fit the profile of a traditional drug developer. Its commercial opportunity depends on adoption of its platform by academic institutions, pharmaceutical companies, and other life sciences customers. The company’s distinguishing feature is its focus on ultra-sensitive protein measurement, a segment of proteomics that is gaining attention as researchers look for earlier, less invasive ways to understand and monitor disease.